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Abstract
Background: Targeting conserved proteins of bacteria through antibacterial medications has resulted in both the
development of resistant strains and changes to human health by destroying beneficial microbes which eventually become
breeding grounds for the evolution of resistances. Despite the availability of more than 800 genomes sequences, 430
pathways, 4743 enzymes, 9257 metabolic reactions and protein (three-dimensional) 3D structures in bacteria, no pathogen-
specific computational drug target identification tool has been developed.
Methods: A web server, UniDrug-Target, which combines bacterial biological information and computational methods to
stringently identify pathogen-specific proteins as drug targets, has been designed. Besides predicting pathogen-specific
proteins essentiality, chokepoint property, etc., three new algorithms were developed and implemented by using protein
sequences, domains, structures, and metabolic reactions for construction of partial metabolic networks (PMNs),
determination of conservation in critical residues, and variation analysis of residues forming similar cavities in proteins
sequences. First, PMNs are constructed to determine the extent of disturbances in metabolite production by targeting a
protein as drug target. Conservation of pathogen-specific protein’s critical residues involved in cavity formation and
biological function determined at domain-level with low-matching sequences. Last, variation analysis of residues forming
similar cavities in proteins sequences from pathogenic versus non-pathogenic bacteria and humans is performed.
Results: The server is capable of predicting drug targets for any sequenced pathogenic bacteria having fasta sequences and
annotated information. The utility of UniDrug-Target server was demonstrated for Mycobacterium tuberculosis (H37Rv). The
UniDrug-Target identified 265 mycobacteria pathogen-specific proteins, including 17 essential proteins which can be
potential drug targets.
Conclusions/Significance: UniDrug-Target is expected to accelerate pathogen-specific drug targets identification which will
increase their success and durability as drugs developed against them have less chance to develop resistances and adverse
impact on environment. The server is freely available at http://117.211.115.67/UDT/main.html. The standalone application
(source codes) is available at http://www.bioinformatics.org/ftp/pub/bioinfojuit/UDT.rar.
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Introduction
Most drugs exert therapeutic effects by binding and regulating
the activity of a particular protein, set of proteins or nucleic acid
targets in the pathogenic microbes. The identification and
validation of such targets compose an important step in drug
discovery process [1,2]. Despite beneficial impacts of antibacterials
in curing infectious diseases, these molecules reach the environ-
ment through excretion or accidental leakages. The molecules
then kill beneficial microbes (agricultural, industrial or of other
importance) and non-pathogenic bacteria, including probiotic
bacteria which are indispensable for survival of humans and
animals. These adverse effects arise due to antibacterial drugs
targeting common proteins in bacteria without discriminating
between pathogenic and non-pathogenic. Studies have shown that
up to 90 percent of the antibiotics used are excreted out and able
to reach water reservoirs without metabolizing. These antibiotics
reside in water reservoirs even after ‘water treatment’ designed to
remove waste and toxic materials. These water soluble antibiotics,
due to prolonged interactions with bacteria, stimulate bacterial
metabolism leading to the selection and maintenance of antibiotic
resistance genes which were acquired through horizontal gene
transfer [3]. Use of antibacterials also produce side-effects and
disturbs probiotic host microbiota resulting in not only gastroin-
testinal tract problems but also increases susceptibility of human to
enteric pathogens [4]. Since evolutionary conservation of some
receptors and metabolic pathways has been preserved in plants
and bacteria, antibacterial (antibiotics) drugs also target protein
receptors in plants and disturb various processes such as
chloroplast replication by fluoroquinolones; transcription and
translation processes by tetracyclines macrolides, lincosamides,
P-aminoglycosides, and pleuromutilins; metabolic pathways for
example folate and fatty acid biosyntheses through sulfonamides
and triclosan, respectively [5].
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among bacteria is also an important causative factor for the
development of drug resistance. Fluoroquinolone-resistance was
observed in new tuberculosis (TB) patients who were administered
with a commonly used antibiotic, fluoroquinolones (more than 10
days), for the treatment of sinusitis, pneumonia, urinary tract
infection, etc. prior to their diagnosis of TB. The chance and
extent of resistance to TB was proportional to period of
consumption of fluoroquinolones [6]. When people infected with
inactive Mycobacterium tuberculosis were administered fluoroquino-
lones for the treatment of sinusitis, pneumonia, etc., since these
antibiotics target DNA gyrase (topoisomerase II) and topoisomer-
ase IV, the inactive M. tuberculosis evolved to fluoquinolones-
resistant strains. The drugs intended to kill Streptococcus pneumoniae
also targeted M. tuberculosis as the targets were common in both the
pathogens [6]. A potential link was established between the use of
fluoroquinolones for the treatment of bacterial infections (other
than Clostridium difficile) and the development of more virulent
strains of C. difficile infection in hospitalized patients arising due to
common drug target [7].
Various drug target identification techniques [8,9] have been
developed by analyzing disease relevance, functional roles,
expression profiles and loss-of-function genetics between normal
and disease states [10–14]. Most of the computational methods are
based on detection of sequence and functional similarity to known
targets and drug-binding domain families affiliation [15,16].
Structural analysis parameters that describe polar and apolar
surface areas, surface complexity, and pocket dimensions have also
been used to identify drug targets [17]. Most of the earlier
databases, servers and programs such as PDTD database [18],
TarFisDock [19] and InvDock (http://bidd.nus.edu.sg/group/
softwares/invdock.htm) required 3D structure of protein to
determine its drug target potential. These methods were less
effective in finding targets that exhibit no or low homology to
proteins with available 3D structures, known targets and proteins
involved in disease process. Support vector machine (SVM) based
methods have been developed from amino acid sequence-derived
properties of known and research targets to predict druggable
proteins from bacterial proteome sequences [20,21]. These SVM
methods are having the problems of overprediction. These
methods are expected to predict proteins highly similar to human
and nonpathogenic sequences as human and conserved proteins
from bacteria(both pathogenic and non-pathogenic) were used for
training and development of SVM. Moreover, none of these
computational methods are available online to the users for
identifying specific targets in any pathogenic organism despite the
availability of numerous genome sequences and colossal amount of
biological information on bacteria. The earlier computational
methods neither addressed adverse effects of antibiotics on
beneficial microbes in the environment nor the development of
resistant strains. Also, those methods did not provide any
information about the biological function of a target which is a
significant parameter. The development of a freely accessible
pathogen-specific computational drug target identification method
supported through a server would enable decision processes
considering several parameters at a time on one platform. The
server would also ease the tedious job to analyze and correlate
information from multiple datasets and applications individually
for each protein which otherwise has been a stumbling block for
researchers in choosing the best target(s) in an automated manner.
A web server, named as UniDrug-Target, which provides
potential bacterial pathogenic-specific drug targets from given
proteome(s) sequences, has been developed. The server compares
proteome sequences of pathogenic strain(s) against sequences of
nonpathogenic and beneficial strains of bacteria as well as human
proteomes to identify unique proteins in the former. Information
about the biological roles of unique proteins in pathogenesis or
protection from the host is also provided. The importance of a
unique protein as a potential drug target is determined on the basis
of its functional importance, i.e. essentiality in cell survival,
chokepoint property (enzyme catalyzes a reaction in which either a
substrate/product is uniquely consumed/produced), function and
domain information, involvement in different pathways, and
disturbances in metabolite productions by targeting pathogen-
specific enzyme by a drug. The essential genes of an organism
constitute its minimal gene set which would be sufficient to sustain
a functioning cellular life form under most favourable conditions
[22]. Since end metabolite production within a pathway depends
upon sequential completion of all reactions in a pathway and
supporting reactions from other pathways, therefore, inhibition of
any enzyme in the upstream regulating reactions would lead to
cessation of its production and might cause disturbances in various
dependent metabolic pathways which use the given end metabolite
as a substrate. It is expected that the inhibition of a unique
chokepoint enzyme would lead to either accumulation of the
unique substrate (potentially toxic to the cell) or starvation of the
unique product (potentially crippling essential cell functions) as no
other shunt path would be available to execute the reaction.
Chokepoints are, therefore, considered as good drug targets and
more than 85% of the reported drug targets of Plasmodium
falciparum are chokepoints [23]. The chokepoints which produce or
consume essential metabolites have been proposed as drug targets
and the analogs for essential metabolites binding to the
chokepoints were proposed as drugs [24]. As metabolic processes
work in coordination with one another in a living system forming
metabolic networks which share or transfer the metabolites within
it, disturbance in one of the elements in a metabolic network
(enzyme/pathway) would result in metabolite imbalances which in
turn will have serious repercussions on the pathogen’s survival.
The server, therefore, provides information related to pathways
getting disturbed by inhibiting or disrupting a given unique
enzyme. The server also provides information about the residues
conserved at the domain level and 3D spatial arrangements of
residues at the cavity site with uniqueness in composition of
residues forming cavities in the pathogenic organisms compared to
the nonpathogenic and human sequences. The server predicts
unique cavity information for potential targets so that the drugs
designed against those cavities would not bind to beneficial/
nonpathogenic organisms. The utility of web server has been
demonstrated in M. tuberculosis.
Materials and Methods
Data Collection and Generation
The computational methods used to collect and generate data
are described here under:
Proteomes information. Proteomes for the construction of
web server were collected from the NCBI (ftp://ftp.ncbi.nih.gov/
genomes/Bacteria/all.faa.tar.gz). Classification of bacterial species
into pathogenic and non-pathogenic was done by using genome
project information given for each organism by the NCBI genome
browser (http://www.ncbi.nlm.nih.gov/sites/genome). GI(NCBI
GenBank Id) No. and corresponding synonymous names were
collected from all.ptt file in the NCBI (ftp://ftp.ncbi.nih.gov/
genomes/Bacteria/all.ptt.tar.gz) and annotation information was
used for clustering proteins into their respective KO(KEGG
orthologous) groups. Sequences of human proteome were
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Enzymes, Reactions, Pathways and Metabolites
Data. Pathways, reactions, compounds and proteomes of all
bacteria were collected from the KEGG FTP (ftp://ftp.genome.
jp/pub/kegg). Enzymes in bacterial proteomes were classified
according to their EC No.(Enzyme Classification Number)(ftp://
ftp.genome.jp/pub/kegg/genes/fasta/genes.pep). Reaction data
source (ftp://ftp.genome.jp/pub/kegg/ligand/reaction/reaction)
was used to identify enzymes and metabolites involved in a
reaction, and development of metabolic networks. Compound
(metabolite) file was collected from the KEGG(ftp://ftp.genome.
jp/pub/kegg/ligand/compound). Pathways represented in
module files at the KEGG (ftp://ftp.genome.jp/pub/kegg/
module/module) were used to collect reactions involved in a
pathway and the order of reactions, and orthologous genes in
different organisms involved in corresponding pathways. The
whole data sets mentioned above were used for the development of
bacterial partial metabolic networks (PMNs).
Essential Genes. The essential gene sequences were
retrieved from database of essential genes, DEG 5.0 [25].
Chokepoints. Chokepoints reaction analysis was done
through in-house developed Perl scripts for 9,257 metabolic
reactions resulting in the identification of 2,754 and 2,957
reactions in all bacteria which uniquely consume and produce
metabolites, respectively. Chokepoint enzymes and their
corresponding ranks for 386 pathogenic and non-pathogenic
organisms were taken from Rahman et al. [26,27]. The ranks of
chokepoint enzymes for individual organisms were stored in a flat
file along with their synonymous names and GI information.
These chokepoint sequences were stored in a database called as
Chokepoint sequence database.
Domain information. Protein domains reported in the
PFam (ftp://ftp.ddbj.nig.ac.jp/mirror_database/pfam/pfam-A.
fasta) were used to identify low-matching conserved regions in
unique pathogen protein sequences. These conserved regions were
used to determine structure and functional variations at residue
level among protein sequences from pathogen, non-pathogen and
human at matching domain regions.
Active sites information. The 3D structures of proteins
were collected from the protein data bank (PDB) (http://www.
rcsb.org) and possible active sites and pockets were identified by
using fpocket program [28]. For all structures, the residues
identified by fpocket involved in the pocket formation along with
chains were extracted using Perl scripts and were stored in flat files
for their further use in determining functionally important residues
in pockets.
Clustering of proteins in bacteria to KO groups. From
the .ptt files (collected from ftp://ftp.ncbi.nih.gov/genomes/
Bacteria/all.ptt.tar.gz), KEGG orthologous group names were
retrieved for already annotated protein sequences. For sequences
in which KEGG orthologous annotated information was not
available, those were clustered to the best possible matching KO
groups at sequence level so as to provide possible protein’s
biological role in bacteria.
The above mentioned data sets were collected or generated,
reorganized and integrated as back end information in the
UniDrug-Target server for automatic analysis.
Algorithms
Identification of chokepoints. The metabolic reactions
which either uniquely consume or produce metabolites were
identified from the metabolic network information collected from
KEGG FTP using perl scripts. Chokepoint enzymes were
identified for 843 bacterial proteomes. Chokepoint reactions in
bacterial metabolic networks were detected by identifying
reactions uniquely consuming a substrate or producing a
product in such a way that the reaction is not an end step in the
entire metabolic network and connecting to multiple reactions
present in various pathways. For these reactions, partial metabolic
network (PMN) under its influence was provided in a hierarchical
tree of pathways which showed the effect on metabolic network of
bacteria by inhibiting the enzymes catalyzing respective
chokepoint reactions.
Identification of interruption sites/points (Enzymes) in
metabolic pathways and corresponding end metabolites
production. Considering the reaction catalyzed by an enzyme
as a starting point, the PMNs under the influence of the enzyme
catalyzing set of reactions (directly or indirectly) were constructed.
These were constructed in a hierarchical tree by using breadth first
search method to traverse and add metabolic reactions. Paths
leading to end metabolites for each enzyme reported in bacteria
were determined based upon the assumption that the cell always
maintains steady state for intermediate metabolites. The products
of metabolic reactions are immediately consumed as substrates by
the next subsequent metabolic reactions existing in the same
pathways and only end metabolites are transferred from one
pathway to the next in a metabolic network.
To identify pathways dependent (directly or indirectly) upon an
enzyme from the identified unique proteins, the reaction catalyzed
by the given enzyme was considered as a starting point. From this
point, traversal of metabolic processes in the same pathway
(mimicking the same order in which they execute in natural
environments by considering product of previous reactions as
substrate for the current reaction and end metabolic reaction
products are not consumed by any reaction in the same pathway)
was continued until the end metabolic reaction in the same
pathway. Once the end metabolites were determined, the
pathways in which the end metabolites were acting as substrates
were identified, and the reactions initiated by these end-
metabolites were considered as starting points for identifying next
set of end metabolites in respective pathways. The pathways where
first set of end metabolites were used as substrates determined the
next level of pathways in the hierarchical tree dependent indirectly
on a given enzyme. This process was iteratively repeated until no
further metabolic pathway gets added into the network. The
pathways were represented in a hierarchical tree in the order as
they were identified and pathway repetition was not allowed. Perl
scripts were written to construct all the PMNs in bacteria and
pathways getting affected by inhibiting an enzyme (from unique
proteins) using metabolic network information from the KEGG ftp
location. The Perl scripts can be obtained from standalone
distribution which currently containing information about 151
metabolic pathways and 9257 metablolic reactions. User can
construct new reactions along with their asscociated enzymes and
new pathways to construct dynamic pathway connectivity
networks by including upcoming metabolic network information.
Identification of metabolic pathways disturbed by
inhibition of dihydropyrimidine dehydrogenase (NADP+)
of M. tuberculosis. The enzyme, dihydropyrimidine
dehydrogenase in pyrimidine metabolism pathway, catalyzes the
reaction, R00978 and consumption of its products by subsequent
reactions results in the synthesis of two end metabolites: Urea
(C00086) and Malonate (C00383) (Figure 1). The former
metabolite can be synthesized by other pathways whereas the
latter is produced only by this pathway; therefore, inhibition of this
enzyme not only ceases the production of this metabolite but also
will impact pathways which use this metabolite as a substrate. The
UDT: Pathogen Specific Drug Target Predictor
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).pathways which use C00086 and C00383 as substrates are given in
(Figure 1) (Level 2 section). Starting from the reaction(s) initiated
by the end metabolites, C00086 and C00383, as substrates, the
metabolic paths were traced to identify end metabolites in the
respective connected pathways, and involvement of newly
determined end metabolites as substrates in various other
pathways and their end metabolites were determined.
Connecting pathways using end metabolites iteratively
(connecting pathways with the help of end metabolites) enabled
to construct hierarchical tree of pathways by the order in which
they appeared in the trace. Through this method, pyrimidine
metabolism pathway has been connected with the pathways under
its direct influence and subsequently end metabolites of the
connected pathways under its direct influence were used to
identify further connected pathways (Figure S1). This type of PMN
analysis was done for all enzyme catalyzed reactions in entire
bacterial networks and then mapped to 843 bacterial systems.
Identification of variations at functional sites to
determine site specific uniqueness in pathogen protein
sequences. Identification of low-matching protein sequences
through similarity score and E-value of the BLAST is not always
sufficient to determine the uniqueness of site in a drug target. As
proteins preserve certain residues to carry out their functions in
various organisms, the conserved residues within the low-matching
regions of non-pathogenic and human sequences matching with
the sequences of the pathogen were identified to determine
whether functionality is preserved or not. For this purpose, low-
matching unique protein sequences in the pathogenic organisms
were matched with the Pfam domain family sequences to
determine the presence of signature domains. The presence of
domains in pathogen-specific proteins was checked in non-
pathogenic and human proteomes. Low-matching domain
regions of the pathogen-specific proteins were further analyzed
for functionally important residues, which might be conserved in
the low-matching proteins of non-pathogenic and human proteins.
The matching domain sequences were further analyzed with the
sequences of PDB database to map the domains on the available
3D structures and also to determine 3D orientations of the
conserved residues within the domains. The conserved residues
between the unique pathogen proteins and Pfam domain
sequences involved in pocket formation were analyzed for their
matching residues in non-pathogenic and human sequences to
determine the amount of variability at the functional sites. The
pathogen-specific unique sequences not showing the presence of a
domain in the Pfam were matched as such with the available 3D
structures to identify surface and pocket residues, if any, which
may be involved in protein-protein and protein-substrate (drug)
interactions. The protein cavites in which surface pocket residues
were found in pathogen-specific sequences were also checked for
residues in the non-pathogen and human proteins. As a result, the
pathogen proteins variable at cavity sites with the non-pathogen
and human proteins could be considered as better targetable sites.
Identification of critical residues that might be involved in cavity
formation was done with the help of pocket information available
from their respective matching PDB structures. Pathogen-specific
protein sequences which were not having the exact match with the
PDB database were analyzed through structures with low-
matching sequences. The process undergoes as follows: pathogenic
sequences were matched to the PDB sequences to collect matching
3D structure of the protein sequence (if high matching is not
available then low-matching 3D structures were considered). All
possible matching 3D structures information was used for guiding
Figure 1. Metabolic paths identified until end metabolite synthesis in pyrimidine metabolism (00240) connected pathways starting
from the reaction (R00978) catalyzed by the enzyme, dihydropyrimidine dehydrogenase (NADP+ [EC: 1.3.1.2], KEGG Orthologous
Id: K00207).
doi:10.1371/journal.pone.0032833.g001
UDT: Pathogen Specific Drug Target Predictor
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32833the user to identify critical residues and to determine their
importance in cavity formation. These matching PDB sequences
were then matched with the non-pathogen and human sequences.
Matching residue positions were noted in all matching pathogenic
and non-pathogenic sequences w.r.t. cavity forming residues for
each matching 3D structure. The variability in residues forming
the same cavity in pathogenic and non-pathogenic organisms
indicates the uniqueness of the pathogenic-specific cavity and
could be used to develop pathogen-specific drugs. Identification of
critical residues in pathogen sequences involved in cavity
formation has to be done by considering set of structures which
cover the entire pathogen sequence at sequence level and different
chains of the matching structures to cover the cavity forming
residues from the unique cavity information generated by server,
Unidrug-Target.
Server Architecture and Implementation
UniDrug-Target is an online web server developed to help user
for easy identification of drug targets in pathogenic bacteria
(Figure 2). User/client may refer to a tutorial available at the
server’s site to gain familiarity.
Client interface. Front-end was developed using HTML
language which provides computational methodology in detail to
identify pathogen-specific drug targets. To use this tool, the client/
user needs to connect the server’s home page available at URL
location: http://117.211.115.67/UDT/main.html. User is
required to click on ‘Click here to execute the server’ and then
he/she can submit a new request to identify unique targets by
selecting set of pathogenic and non-pathogenic organisms. After
job submission, an html page link where output will be available is
generated and user may bookmark it for later use to track on the
status of a job. Initially status of the job will be ‘pending’. User can
use the same address to know the status and whenever it changes
to ‘Result’, he/she can click on the ‘Result’ button to retrieve final
results. Jobs are processed in a queue and time required for
completion of a given job is dependent on number of tasks pending
in the server.
Server. The server was developed using CGI-Perl
programming language by implementing multithreading and
socket programming. The server has two threads interacting
with a backend database developed on MySQL server. The
backend database has ‘Transaction’ table having transaction_id,
set_of_pathogenic strains, set_of_nonpathogenic strains, and status
as its fields (Figure 3).
Once the server gets started, it initiates two threads: ‘client
thread’ and ‘main thread’. The client thread waits until a socket
gets connected, and once the socket gets connected, it takes
pathogenic organisms list, nonpathogenic organisms list and
inserts a new row into the transaction table for storing the
respective fields information with status field information as
‘pending’ and waits for another socket to get connected. When
main thread gets initiated, it extracts first pending transaction (job)
in the transaction table and executes Perl scripts to implement the
processes given in the flow diagram in Figure 2. Once a particular
Figure 2. Flow diagram representing methodology implemented in UniDrug-Target server to identify potential pathogen-specific
drug targets.
doi:10.1371/journal.pone.0032833.g002
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status field value transaction table to ‘Result’ from ‘pending’.
Three hyperlinks (Complete HTML format, HTML/CSV format
and Download HTML/CSV format) are generated on the place
of later so that the user can retrieve results. The results will be
stored at the site for a maximum time of one month. The main
thread retrieves next pending transaction and repeats the above
mentioned procedures.
Data Representation
Once the user clicks on hyperlinks available in status column,
the output is given in a table format with columns containing
following information: 1. Serial No., 2. Highest matching non-
pathogenic protein similarity score (in percentage), 3. GI number/
synonymous name of the unique protein, 4. Essentiality of a
unique protein or its similarity with the known essential proteins,
5. Protein function as a chokepoint or not along with its rank, 6.
Whether unique protein is highly similar to known chokepoint
enzymes in other pathogenic organisms along with rank(applicable
for organisms in which chokepoint enzymes and ranks were not
reported), 7. Hyperlink to the enzyme and its reactions data along
with reactions uniquely consuming or producing metabolites with
pathway connectivity graph starting from each reaction catalyzed
by the enzyme (applicable when unique protein is an enzyme), 8.
KEGG orthologous group ID, 9. Hyperlink to the pathways in
which the protein is involved along with the pathway connectivity
diagram, 10. Maximum similarity between unique protein and
human proteome, 11. Domains and non-conserved residues
information in pathogenic organism compared to non-pathogenic
and 12. Unique active site information of pathogen protein
sequences along with non-pathogen matching residue information.
Implementation
The web server has been constructed by using CGI-Perl scripts
with backend data developed from the available bacterial genome
sequences and biological information represented in ‘data
collection and generation’ section. Programs were developed for
the identification of unique proteins at sequence level in
association with standalone BLASTp when protein sequence of
a pathogen fulfils two conditions one after another: sequence
should be less than 30% similar (in entire length) with the proteins
of beneficial bacteria or human and E-value greater than 0.0001.
The output of two bacteria (M. tuberculosis H37Rv, Bacillus anthracis
str. Ames) was checked manually and found that the above criteria
were sufficient to identify pathogen-specific proteins in a
proteome. These unique proteins were matched/compared with
the database of essential bacterial proteins, enzyme sequences in
the chokepoint database, data on proteins related to various
pathways determined from orthologous genes involved in a
pathway, and sequences of human proteome. Three new
algorithms were developed and implemented into the server by
using protein sequences, domains, structure, and metabolic
reactions for; i. Construction of partial metabolic networks (PMNs)
to determine extent of disturbances in metabolite production by
targeting a protein; ii. Determination of conserved critical residues
involved in protein-protein interactions, cavity formation and
biological function at domain-level with low-matching sequences;
and iii. Variation analysis of residues forming similar cavities
Figure 3. UniDrug-Target architecture.
doi:10.1371/journal.pone.0032833.g003
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identify cavities specific to pathogen. The server provides all the
information mentioned in this section for each pathogen-specific
protein in the order explained in ‘data representation’ section.
Results
The web server, Unidrug-Target, has been designed to identify
pathogen-specific unique drug targets in bacteria by indicating
their pathogen specificity upto structural (cavity) and functional
level. Data sets representing protein’s functional importance and
their potential to be considered as drug targets were generated by
analyzing various available resources which were interconnected.
Three new algorithms were developed and implemented as Perl
scripts for PMNs construction to determine the affect of targeting a
protein on metabolite disturbance in pathogen survival; domain
level conservation among the low-matching pathogenic, non-
pathogenic and human sequences to predict functional importance
of low-matching regions and their role in representing critical
residues such as surface residues involved in protein-protein
interactions and cavity formation residues for protein-ligand
interactions; and unique cavity identification in predicted unique
proteins at sequence level to determine variability among the
residues forming the same cavity in pathogenic and non-
pathogenic organisms. The execution of this server is very simple
and the user has to select pathogenic and non-pathogenic strains
from the lists available at the server’s website. The server provides
list of unique proteins with their functional importance in an
automated manner so that the user can make final decision on
selection of a particular unique protein as a drug target.
The functional and other important features of unique proteins
such as their essentiality in cell survival, chokepoint property,
biological function, involvement in pathway(s) and inhibition of
metabolite’s production, residues conservation at domain level
between proteins from non-pathogenic and pathogenic and
residue sets forming unique composition at the cavities, which
are specific to pathogen are provided by the server. The server also
provides qualitative information regarding uniqueness of cavity at
residue level for all unique proteins in the pathogens. Algorithms
were also developed, implemented and incorporated into the
server to provide choke point target efficiency, uniqueness at
domain level and identification of cavity and surface residues of all
predicted unique proteins. The relevance of developed algorithms
in the prediction of unique proteins as drug targets is given below:
Identification of chokepoint reaction efficiency of
pathogen-specific proteins
Inhibition of unique proteins (enzymes) leads to interruption in
consumption or production of a metabolite. Since no alternative
enzyme or reaction in the bacterial system is available for
chokepoint reaction(s), inhibition of unique chokepoint enzyme(s)
involved in the consumption or production of a given metabolite
may lead to accumulation or depletion of the metabolite in a cell
which will be detrimental to the survival of pathogen. Analysis of
disturbances in metabolite formation and pathways provides
insight on potential of unique protein as a drug target. For
example, K00189, KEGG orthologus group represents the
enzyme, 3-Methyl-2-oxobutanoate dehydrogenase (EC: 1.2.7.7)
which catalyzes the reaction involved in the production of 2-
Methyl-propanoyl-CoA from 3-Methyl-2-oxobutanoic. The me-
tabolite, 2-Methyl-propanoyl-CoA, is not produced by any other
enzyme coordinated reactions or by any other pathway except
valine, leucine and isoleucine degradation pathways. Starting from
this reaction, the entire set of reactions in valine, leucine and
isoleucine degradation pathway were traced upto the end
metabolite, succinoyl-CoA, which is used as a substrate by 4
other metabolic pathways: citrate cycle, 1- and 2-methylnaphtha-
lene degradation, benzoate degradation and reductive carboxylate
cycle (involved in CO2 fixation). Benzoate degradation pathway
further regulates several other pathways and the entire list of
pathways under the influence of the enzyme can be seen Figure
S2. This type of analysis is provided for all predicted proteins
having annotated or highest possible match with the respective
clusters of orthologous groups from the KEGG (KO groups). The
drug target potential of each unique protein can be determined on
the basis of relevance of these pathways in bacterium’s
pathogenesis and survival. Similarly, user can retrieve information
on disturbances in pathways and metabolite production for any
pathogen-specific enzyme of a bacterium by using the server. In
standalone application, new pathways can be constructed, and
even an entire new pathway connectivity diagrams can be
reconstructed w.r.t. upcoming information.
Identification of uniqueness in pathogen-specific
proteins at the domain level
Similarity and dissimilarity among the residues in a common
domain between the pathogenic and non-pathogenic protein
sequences was analyzed to determine uniqueness in the pathogen-
specific protein domains. This analysis would be useful in
identifying conserved residues in low-matching regions because
those residues might be important in preserving functionality
which is otherwise difficult to predict directly from the compar-
ative analysis between pathogenic and non-pathogenic sequences.
This analysis is further extended to the identification of conserved
residues involved in the cavity formation. For this purpose, the
protein’s domain sequence is mapped to available 3D protein
structure so as to identify varying critical residues of interest
involved in pocket formation between pathogen and non-pathogen
sequences from low-matching regions. For example, one of the
predicted targets, gi:15607938 in M. tuberculosis, matched with a
region within Q743F5_MYCPA (Swissprot id) sequence contain-
ing Linocin_M18 (Pfam_id: PF04454.6) domain and the target
showed low-matching with a set of sequences (GI: 108797777,
119866868, 126438337, 108802357, etc.) in the non-pathogenic
organisms. The conservedness between pathogenic and non-
pathogenic sequences w.r.t. their residue position matching with
the domain sequence along with the role of matching position in
pocket formation can be deciphered (Table 1).
Identification of unique cavity sites in pathogen-specific
proteins
Uniqueness of cavities at residue level provides information
related to the site to be targeted by drug molecules. Though this
method requires user to analyze the output of the server manually
to take a decision, still it provides possible residues in the cavities
that are common among proteins of pathogen, non-pathogen
and/or human, and also residues specific to the pathogen protein
cavity. The tool can predict unique cavity information even for
proteins for which 3D structures are not available by combining
the information obtained from different low-matching known 3D
PDB structures and their chains. For example, a pathogen-specific
unique protein gi:15607942 with a known 3D structure (PDB ID:
2VZZ) [29] with three chains (A, B & C) is analyzed with low-
matching 3D structure with PDB ID: 2VI7 to validate the
algorithm designed for predicting possible pocket forming residues
from the low-matching 3D structures for those protein sequences
in which 3D structures are not available. The 3D structure of
UDT: Pathogen Specific Drug Target Predictor
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and A & B, respectively. The residues forming pocket in 2VI7
structure are given in Table 2. From the matching data,
corresponding pocket residues (refer to algorithms in materials
and methods section) in 2VZZ, gi:15607942 are given in column 3
of Table 2. The predicted residues formed pocket in structure
2VZZ (Figure 4). These pocket forming residues were matched in
non-pathogenic sequences to determine corresponding pocket
forming residues and then unique or identical nature of the pocket
in pathogenic is determined on the basis of dissimilarity or
similarity of residues, respectively. Since equivalent pocket residues
are different between the pathogenic and non-pathogenic
sequences (Table 2), this pocket may have unique structure in
the pathogen protein. The web server provides comparative
analysis for each cavity present in each predicted unique sequence
of pathogen by matching with available PDB structure informa-
tion. The analysis will pinpoint cavities to be targeted within
functionally important proteins so that the drug(s) developed
against these pockets will not interact with the beneficial/non-
pathogenic organisms and humans. A sample file for analysis is
provided in tutorial at website of the server.
Discussion
The ‘UniDrug-Target’ web server is first of its kind and can
identify potential pathogen-specific drug targets in bacteria. Drugs
designed and used against those targets may cause few ecological
problems and mitigate the problem of drug resistance. Bacterial
strains with resistance to all but a single drug do exist, and some
strains may soon have no effective treatments left in the ‘‘medicine
chest’’. The Staphylococcus aureus has developed resistance to
penicillin, methicillin, tetracycline and erythromycin in a sequen-
tial order over the last fifty years and half of all its infections in the
US were due to antibiotic resistant strains in 1991. This outcome
left vancomycin as the only effective agent against the bacterium
but surprisingly, strains resistant to this drug has also been
identified in 2002 [30,31]. Multidrug-resistant strains of Enterococ-
cus faecalis and E. faecium have also shown resistances in the
sequential order [32]. Penicillin and other beta-lactams resistances
in S. pneumoniae are increasing worldwide and the major
mechanism of resistance involves the occurence of mutations in
genes encoding penicillin-binding proteins [33]. All strains of M.
tuberculosis have shown resistance to known drugs. Recent studies
have shown that few strains of M. tuberculosis have gained resistance
to most effective drugs, isoniazid and rifampin [34]. Therefore,
drug resistance emerged as a threat to established treatment.
Fast identification of effective and novel pathogen-specific drug
targets is important in order to keep pace with the rapidly evolving
drug resistance strains of bacterial pathogens. The web server,
Unidrug-Target, has been designed to identify pathogen-specific
proteins and their functional importance so that a user can make a
decision regarding potentiality of a given protein to be used as a
drug target. The predicted potential drug targets, through this
server, will have the advantage of causing fewer adverse affects on
humans as well as beneficial bacteria existing in the environment.
As pathogenesis and survival processes differ among bacteria, this
tool provides detailed information regarding unique proteins and
leaves it to the user to take final decision on a given protein’s drug
Table 1. Sample analysis report of one of the pathogen-specific protein (gi:15607938) of M. tuberculosis to determine domain-level
conserveness in low-matching sequences between pathogen-specific and non-pathogenic protein sequences
f.
Pathogenic sequence: F E G Y S A A S I E G I R S A S
15607938
Matching domain F E G Y G A A S I E G I R S S S
sequence:Q743F5_MYCPA
Domain name:Linocin_M18
Conserved residues between F E G Y A A S I E G I R S + S
pathogenic and domain
sequence
w
Matching
nonpathogenic
sequence_ids
F + GY+ AA + EGI + A 108797777
F + GY+ AA + EGI + A 119866868
E + E I 108802357
E + E I 119871510
E + E I 126438337
FEG A I + 108799508
FEG A I + 119868621
FEG A I + 108799508
3fdx_A 0 0 2 0 2 2 2 2 2 2
Pocket numbers
y
fFor detail see Algorithm section in ‘Material and Methods’.
wResidue, +, blank and - indicate identity, similarity, dissimilarity and gap, respectively w.r.t. corresponding residues in pathogenic sequences in equivalent positions.
yDifferent residues forming a given pocket are represented by a number, i.e. 0 indicates biggest size pocket in a protein.
doi:10.1371/journal.pone.0032833.t001
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has been provided in an automated fashion by integrating diverse
data: essentiality in cell survival, chokepoint property, biological
function, involvement in pathways, pathways and metabolite’s
production getting disturbed by inhibiting unique proteins
(enzyme cases only), sets of residues conserved at domain level
between non-pathogenic and pathogenic organisms, and unique
composition at the cavities specific to the pathogen by using
known domain sequence and pocket information of available 3D
structures in the PDB. The objective of the last parameter has
been to provide unique cavities in a predicted protein target so
that drugs designed against those cavities do not bind to any
nonpathogenic organism. The computational method can point
out residues which are surface exposed and forming unique cavity
even for a protein without 3D structure.
UniDrug-Target is the first web server which provides potential
pathogen-specific drug targets from proteome sequences based on
their functional importance. Though many computational meth-
ods for identification of drug targets have been reported, but
limitations in those computational methods impede their applica-
tions and usage. Li and Lai included only known human drug
target sequences to train support vector machine (SVM) for the
prediction of drug targets and, therefore, the method will unlikely
predict unique drug targets in the bacterial pathogens [20].
Hopkins and Groom proposed ‘Lipinski rule-of-five’ (LR5)
compliant molecule binding domain containing proteins which
are not matching with any human sequences to be drug targets
[15]. Hasan et al. applied the above principle to predict 354 drug
targets in M. tuberculosis [16]. However, most of the proposed drug
targets were present in many beneficial organisms [16]. Han et al.
[21] used known targets from TTD database [35] to train SVM
which predicts drug targets. Their method predicted large number
of drug targets from a proteome (i.e. 845 drug targets out of ~ 4 4000
proteins of M. tuberculosis). Since most of the sequences used for
training the SVM were from human and few from conserved
proteins of bacteria, the predicted drug targets would show high
similarity to the human and nonpathogenic bacterial sequences.
Though their method was able to predict some commercialized
and research targets in M. tuberculosis but from the predicted
targets, most were having either similarity with the human
proteins or non-pathogenic organisms.
Features such as pocket volume, accessible surface area, pocket
compactness, ratio of individual residue frequencies on pocket
surface to that of total surface, etc. are important in protein-
protein interactions (PPIs). A SVM model containing 69 attribute
features was earlier developed which included above mentioned
pocket features to identify drug target potential of a protein from
its 3D structure [36]. Critical residues forming similar pocket in
non-homologous (low sequence similarity) or distinct protein
structures has been identified using clique detection technique
[37]. This finding supports our proposal of the use of low-
matching 3D structures of proteins for the identification of
plausible pocket forming residues in a pathogen-specific protein.
However, the presence of a cavity in a target protein does not
qualify it to be a druggable target because same cavity may be
present in low-matching proteins of beneficial microbes or human
proteomes. Therefore, identification of variation in residues
forming cavity is an important parameter for emphasizing the
protein as a druggable target as suggested in UniDrug-Target.
Drug target efficiency depends on functional role of the target in
metabolic network of a pathogen, therefore, chokepoints have
been proposed as possible drug targets. Rahman et al. proposed
ranking of chokepoints based on number of shortest paths passing
through the reaction catalyzed by the chokepoint enzymes
between any two metabolites in the metabolic network of an
organism and proposed highly ranked enzymes as better drug
Figure 4. UniDrug-Target predicted pocket forming residues (Table 2) of gi:15607942 (PDBID: 2VZZ). Visualization through VMD (www.
ks.uiuc.edu/Research/vmd/) showed that above residues forming a pocket. Pocket forming residues shown in the surface representation.
doi:10.1371/journal.pone.0032833.g004
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mostly housekeeping proteins and are also conserved across all
organisms. Therefore, selecting those chokepoints as drug targets
and developing drugs against those will lead to significant side-
effects on humans and adverse impacts on the beneficial
organisms. Kim et al. used simulated metabolic flux analysis to
propose that a chokepoint reaction utilizing essential metabolite
and inhibition of the enzyme (chokepoint) leading to zero mass
growth in a bacterium to be used as a potential drug target [24].
As stated earlier, this approach is also expected to predict
housekeeping proteins as drug targets. This method also lacked
in representing the extent of impact of inhibition of chokepoint in
a bacterium. In order to identify chokepoints as potential drug
targets, those proteins should be specific to a pathogen and its
potential in regulating metabolic network of bacteria should be
identified. Through PMNs analysis, the server provides the
pathways and end-metabolites to be disturbed by inhibiting a
given unique enzyme. Further, none of the earlier computational
drug target identification methods has mentioned the need to
study proteins involvement in metabolic and signal transduction
pathways to be used as drug targets. The UniDrug-Target
provides the involvement of a given protein in different pathways
so as to understand how a given drug disturbs different pathways.
UniDrug-Target server is expected to be useful to researchers not
only for drug target identification but also for other purposes
because the tool provides unique proteins as well as their functional
information, which the biologists can use to identify the existence of
unique biological processes specific to a pathogen or any bacterium
that might be involved in virulence, pathogenesis, survival,
persistence, etc. For example, when functionalities of predicted
unique proteins of M. tuberculosis were analyzed, majority of the
predicted proteins were found to be involved in persistence which is
characterized largely as a slow metabolic process to overcome
nutrient shortage and anaerobic conditions, changes in chemical
environment surrounding the bacterium, and changes in morphol-
ogy of cell wall surface of bacterium to protect it from immune
responses. Interestingly, the identified unique proteins in M.
tuberculosis were found to be involved in three important stages of
persistence: initiation, continuation of persistence and reactivation
to growth-phase to persistence. Similarly, unique proteins of any
pathogen or a bacterium may be involved in any specific biological
process which could be identified with the help of this server.
Table 2. Identified pocket residues of pathogen-specific protein, gi:15607942, matching with residues forming similar pocket in
nonpathogenic sequences of different organisms*.
Residue position
Residue in pdb
2VI7 Residue in 2VZZ
#
Nonpathogenic sequences residues (positions) along with match
information
in pdb 2VI7 (chain name) & pathogenic sequence
15607942 126433780 126437231 108801252 108800463
93 V(A) L(113) + V(79) + V(121) + V(107) + P(141)
94 A(A) G(114) D(80) A(122) A(108) T(142)
95 V(A) L(115) + P(81) S(123) S(109) V(143) +
97 W(A) Y(117) + Y(83) Y R(125) R(11) -
98 Q(A) Q(118) Q Q(84) Q I(126) I(112) R(144) +
99 G(A) G(119) G G(85) G G(127) G G(113) G G(145) G
101 G(A) G(121) G G(87) G G(129) G G(115) G G(147) G
102 V(A) Y(122) I(88) V(130) V(116) L(148)
103 G(A) G(123) G G(89) G A(131) A(117) G(149) G
104 S(A) T(124) + R(90) T(132) T T(132) T Q(150)
108 G(C) A(128) E(94) A(136) A A(122) A R(154)
111 L(C ) L(131) L L(97) L V(139) + V(125) + L(157) L
112 D(C) Y(132) E(98) + D(140) D D(126) D D(158) D
115 D(C) F(135) D(101) D F(143) F F(129) F D(161) D
116 N(C) A(136) G(102) G(144) G(130) A(162)
131 N(A) N(151) N N(113) N N(159) N N(159) N N(145) N
133 P(A) A(153) P(115) P P(161) P A(147) D(175)
134 A(A) S(154) + A(116) A S(162) + S(148) + N(176)
136 A(A) A(156) A A(118) A R(164) R(150) A(178) A
137 L(A) V(157) + R(90) T(132) + T(118) + Q(150)
138 Y(A) S(158) Y(120) Y L(161) L(152) Y(180)
140 K(A) R(160) + S(122) K(168) K K(154) K R(182) +
141 F(A) N(161) V(123) V(169) V(155) F(183) F
*The number indicates the gi: number. Residue, +, blank and - indicate identity, similarity, dissimilarity and gap, respectively w.r.t. corresponding residues in pathogenic
sequences in equivalent positions.
#gi:15607942 is having an X-ray crystallographic structure with 2VZZ. The predicted residues are forming pocket equivalent to 2VI7.
doi:10.1371/journal.pone.0032833.t002
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targets in bacteria. In some cases, already known targets may be
replaced with new targets and subsequently drugs can be
developed against the new targets. When unique proteins of M.
tuberculosis (determined by comparing proteome sequences of M.
tuberculosis against (see systems and methods) beneficial Mycobacteria
and human) were compared against proteomes of all beneficial
bacteria, majority of the unique proteins (more 150 sequences)
were identified to be having no or few sequence matches (1 or 2)
with the sequences of all beneficial and non-pathogenic organisms.
Even four unique proteins which are not matching with any of the
beneficial organisms are found to be essential: gi:15609964 (a
DNA binding protein implicated in the survival of M. tuberculosis in
the macrophages of the host [38], gi:15610379 (hypothetical
Protein), gi:15607884 (a DNA binding protein involved in
transcriptional regulation), and gi:15607488 (conserved membrane
protein). These proteins could be considered as new generation
perspective drug targets against M. tuberculosis. Since the server is
not pathogen-specific, it can provide potential drug targets for any
pathogenic bacterium and expected to revolutionize pathogen-
specific drug development.
Supporting Information
Figure S1 Partial metabolic network (PMN) under the influence
of pyrimidine metabolism pathway constructed by inhibiting the
enzyme, dihydropyrimidine dehydrogenase.
(TIF)
Figure S2 Partial metabolic network (PMN) predicting the affect
of inhibiting chokepoint reaction (R07160) involved in production
of the metabolite, 2-Methylpropanoyl-CoA from 3-Methyl-2-
oxobutanoic acid.
(TIF)
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